Onyx Pharmaceuticals




Investors        
Onyx Pharmaceuticals

INVESTORS
--------
To Onyx's knowledge, all press releases, scientific papers, and abstracts and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. Onyx has no intention of updating this information, and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

Corporate Presentation

May 2009
[pdf file - 1.4 MB]

Corporate Fact Sheet

February 2009
[pdf file - 89 KB]

Stock Quote

(updated every 15 minutes)
Ticker: ONXX
Quote: 28.82   (+unch)
Today's High: 0
Exchange: NASDAQ

Investor Relations Contacts

Julie Wood
(510) 597-6505

Alexandra Santos
(510) 597-6504

Onyx Pharmaceuticals, Inc.
2100 Powell Street
Emeryville, CA 94608

Latest News

  • Jun. 02, 2009
Onyx Pharmaceuticals To Present At The Goldman Sachs 30th Annual Global Healthcare Conference
  • Jun. 01, 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
  • May 28, 2009
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar® and Tarceva® in Patients with Liver Cancer
  • May 20, 2009
Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
View More Press Releases

 



--------

©2009 Onyx Pharmaceuticals, Inc.